Alejandro Vidal Margenat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alejandro Vidal Margenat has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Ramesh Hariharan
Department of Cardiac Electrophysiology McGovern Medical School University of Texas Health Science Center at Houston Houston Texas USA
3 shared publicationsAhmed G. Zedan
Department of Cardiac Electrophysiology McGovern Medical School University of Texas Health Science Center at Houston Houston Texas USA
1 shared publicationAhmed Zedan
EP Heart University of Texas Houston Texas USA
1 shared publication- Ankur Singla
Department of Internal Medicine Northwest Health‐Porter Valparaiso Indiana USA
1 shared publication Ellen Condoure
Abbott, Houston, USA
1 shared publicationGaurav Bector
Department of Medicine Dayanand Medical College & Hospital Ludhiana Punjab India
1 shared publication
Latest Publications
- 18 June 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Selective Cardioneuroablation for Symptomatic Sinus Bradycardia After Bariatric Surgery: A Report on two Cases
Functional bradycardia, characterized by a heart rate below the normal range due to dysregulation of the autonomic nervous system (ANS), poses a clinical challenge with limited treatment options. Symptomatic sinus bradycardia is an uncommon but potentially significant complication following bariatric surgery. Cardioneuroablation (CNA) has emerged as a novel therapeutic intervention targeting the cardiac ANS to modulate heart rate. This case series describes two patients, with the aim of providing a simplified but successful approach with targeted partial CNA for sinus bradycardia complicating bariatric surgery.
- 18 June 2026
- Published by Wiley in Pacing and Clinical Electrophysiology
Selective Cardioneuroablation for Symptomatic Sinus Bradycardia After Bariatric Surgery: A Report on two Cases
Functional bradycardia, characterized by a heart rate below the normal range due to dysregulation of the autonomic nervous system (ANS), poses a clinical challenge with limited treatment options. Symptomatic sinus bradycardia is an uncommon but potentially significant complication following bariatric surgery. Cardioneuroablation (CNA) has emerged as a novel therapeutic intervention targeting the cardiac ANS to modulate heart rate. This case series describes two patients, with the aim of providing a simplified but successful approach with targeted partial CNA for sinus bradycardia complicating bariatric surgery.
- 7 August 2024
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 68 (1) , 83-91
Targeting pulmonary vein myocardial sleeves with omnipolar mapping can reduce radiofrequency applications and procedure time: a proof-of-concept study
Background There remains an imperative need to accurately map the left atrium in the setting of atrial fibrillation. While the pulmonary vein segmental ostial isolation plays a significant role in atrial fibrillation, clinical attempts to selectively ablate near the pulmonary vein myocardial sleeves have demonstrated a higher recurrence rate of arrhythmia given less precise mapping modalities. However, novel omnipolar mapping technology coupled with Advisor™ HD Grid Mapping Catheter may provide an advantageous profile to map and selectively ablate near the myocardial sleeves. Methods This retrospective cohort underwent ablation targeting the pulmonary vein myocardial sleeves with the use of omnipolar mapping technology and later wide area circumferential ablation (WACA) was performed. Results The findings of this study demonstrated a few number of lesions were required to achieve all PVI targeting PVMS at 36 (95% CI 32–41) compared to WACA at 81 (95% CI 73–90). PVMS radiofrequency time was shorter at 314 s (95% CI 278–350 s) compared to 799 s (95% CI 692–906 s) for WACA. Mean procedure time to complete PVMS was 59 min (95% CI 53–65) and to complete WACA was 90 min (95% CI 80–100). Conclusion Precision ablation near PVMS coupled with omnipolar technology may provide a superior profile in reducing procedure time and number of ablative lesions compared to WACA in the setting of atrial fibrillation with possible similar results. Future investigation using randomized controlled trials can help further support these findings. Graphical Abstract
- 7 August 2024
- Published by Springer Nature in Journal of Interventional Cardiac Electrophysiology
- Vol. 68 (1) , 83-91
Targeting pulmonary vein myocardial sleeves with omnipolar mapping can reduce radiofrequency applications and procedure time: a proof-of-concept study
Background There remains an imperative need to accurately map the left atrium in the setting of atrial fibrillation. While the pulmonary vein segmental ostial isolation plays a significant role in atrial fibrillation, clinical attempts to selectively ablate near the pulmonary vein myocardial sleeves have demonstrated a higher recurrence rate of arrhythmia given less precise mapping modalities. However, novel omnipolar mapping technology coupled with Advisor™ HD Grid Mapping Catheter may provide an advantageous profile to map and selectively ablate near the myocardial sleeves. Methods This retrospective cohort underwent ablation targeting the pulmonary vein myocardial sleeves with the use of omnipolar mapping technology and later wide area circumferential ablation (WACA) was performed. Results The findings of this study demonstrated a few number of lesions were required to achieve all PVI targeting PVMS at 36 (95% CI 32–41) compared to WACA at 81 (95% CI 73–90). PVMS radiofrequency time was shorter at 314 s (95% CI 278–350 s) compared to 799 s (95% CI 692–906 s) for WACA. Mean procedure time to complete PVMS was 59 min (95% CI 53–65) and to complete WACA was 90 min (95% CI 80–100). Conclusion Precision ablation near PVMS coupled with omnipolar technology may provide a superior profile in reducing procedure time and number of ablative lesions compared to WACA in the setting of atrial fibrillation with possible similar results. Future investigation using randomized controlled trials can help further support these findings. Graphical Abstract
- 30 January 2024
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (2) , 222-232
Patients with a high defibrillation threshold: Approaches to management
Implantable cardioverter-defibrillators (ICDs) have revolutionized the prognosis for patients at elevated risk of ventricular tachyarrhythmias. For safety, defibrillation should be effective with a minimum of 10 J below the device's maximum energy. While modern ICDs rarely deliver ineffective shocks in primary prevention, the surge in managing severe heart failure patients has led to an increased number of patients with high defibrillation thresholds (DFTs). This article elucidates the potential causes of high DFT, including clinical factors, lead and device placement, the presence of a Left Ventricular Assist Device (LVAD), prolonged ventricular arrhythmias, shock vectors, waveform tilt, medications, and manufacturer-specific options. We also detail management strategies, highlighting alternative shock coil placements, practical recommendations, and case studies from our institution. Our management algorithm suggests addressing preventable causes, re-evaluating coil positions, considering non-invasive system modifications, upgrading to a higher-capacity device, and adding extra coil(s).
- 30 January 2024
- Published by Wiley in Pacing and Clinical Electrophysiology
- Vol. 47 (2) , 222-232
Patients with a high defibrillation threshold: Approaches to management
Implantable cardioverter-defibrillators (ICDs) have revolutionized the prognosis for patients at elevated risk of ventricular tachyarrhythmias. For safety, defibrillation should be effective with a minimum of 10 J below the device's maximum energy. While modern ICDs rarely deliver ineffective shocks in primary prevention, the surge in managing severe heart failure patients has led to an increased number of patients with high defibrillation thresholds (DFTs). This article elucidates the potential causes of high DFT, including clinical factors, lead and device placement, the presence of a Left Ventricular Assist Device (LVAD), prolonged ventricular arrhythmias, shock vectors, waveform tilt, medications, and manufacturer-specific options. We also detail management strategies, highlighting alternative shock coil placements, practical recommendations, and case studies from our institution. Our management algorithm suggests addressing preventable causes, re-evaluating coil positions, considering non-invasive system modifications, upgrading to a higher-capacity device, and adding extra coil(s).